← Back to Clinical Trials
Recruiting NCT03617939

NCT03617939 A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03617939
Status Recruiting
Phase
Sponsor University of Colorado, Denver
Condition Cancer Risk
Study Type OBSERVATIONAL
Enrollment 20,000 participants
Start Date 2015-09-16
Primary Completion 2035-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Biospeciman CollectionSurvey AssessmentsMedical Chart Reviews

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20,000 participants in total. It began in 2015-09-16 with a primary completion date of 2035-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is not a treatment study. The overall objective is to develop an improved standard of care through studying blood, tissue, biological, etc. samples, that patients have allowed researchers to procure.

Eligibility Criteria

Inclusion Criteria: 1. 18 years of age and older. 2. Diagnosed with cancer, or may be at risk for cancer. 3. Able to understand and sign the TCCP Informed Consent and Research Authorization form directly or through a legally authorized representative (LAR). Non-English speaking subjects will also be invited to participate in the TCCP study, in accordance with COMIRB's short-form consent use. Exclusion Criteria: 1\. Members of vulnerable populations including neonates (birth to 30 days), children (under age 18), wards of the State, prisoners or those on probation or alternate sentencing, or decisionally challenged (adults or children that are cognitively impaired, incompetent to consent, proxy consent, or consenting in life threatening situations).

Contact & Investigator

Central Contact

Kyra Anderson

✉ kyra.anderson@cuanschutz.edu

📞 303-724-3868

Principal Investigator

Virginia Borges, MD

PRINCIPAL INVESTIGATOR

University of Colorado, Denver

Frequently Asked Questions

Who can join the NCT03617939 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Risk. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03617939 currently recruiting?

Yes, NCT03617939 is actively recruiting participants. Contact the research team at kyra.anderson@cuanschutz.edu for enrollment information.

Where is the NCT03617939 trial being conducted?

This trial is being conducted at Aurora, United States, Colorado Springs, United States, Colorado Springs, United States, Denver, United States and 2 additional locations.

Who is sponsoring the NCT03617939 clinical trial?

NCT03617939 is sponsored by University of Colorado, Denver. The principal investigator is Virginia Borges, MD at University of Colorado, Denver. The trial plans to enroll 20,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology